Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M8891 |
Synonyms | |
Therapy Description |
M8891 is an inhibitor of methionine aminopeptidase 2 (MetAP2), which results in cleavage of the aminoterminal methionine residue from an early forming protein, thereby disrupting protein synthesis and potentially result in reduced proliferation of endothelial cells (PMID: 31725285). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M8891 | CS-0109402 | M8891 is an inhibitor of methionine aminopeptidase 2 (MetAP2), which results in cleavage of the aminoterminal methionine residue from an early forming protein, thereby disrupting protein synthesis and potentially result in reduced proliferation of endothelial cells (PMID: 31725285). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 del | lung cancer | resistant | M8891 | Preclinical - Cell culture | Actionable | In a preclinical study, knockout of TP53 conferred resistance to M8891 in a lung cancer cell line as demonstrated by loss of inhibition of colony formation in culture (PMID: 37940144). | 37940144 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03138538 | Phase I | M8891 | M8891 First in Human in Solid Tumors | Terminated | USA | 0 |